Alpelisib [1217486-61-7]
Cat# T1921-10mg
Size : 10mg
Brand : TargetMol
Alpelisib
Contact us for more batch information
Purity:99.73%
Resource Download
COA HPLC HNMR
Alpelisib
Catalog No. T1921Cas No. 1217486-61-7
Alpelisib (BYL-719) is a PI3Kα inhibitor (IC50=5 nM) with selective, potent, and oral activity, inhibiting PI3Kβ/γ/δ with low activity (IC50=250/290/1200 nM). Alpelisib demonstrates antitumor activity and specifically targets PIK3CA mutant tumors.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. Pack Size | |
---|---|
5 mg | |
10 mg | |
25 mg | |
50 mg | |
100 mg | |
200 mg | |
500 mg | |
1 g | |
1 mL x 10 mM (in DMSO) |
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
Description | Alpelisib (BYL-719) is a PI3Kα inhibitor (IC50=5 nM) with selective, potent, and oral activity, inhibiting PI3Kβ/γ/δ with low activity (IC50=250/290/1200 nM). Alpelisib demonstrates antitumor activity and specifically targets PIK3CA mutant tumors. |
In vitro | METHODS: Osteosarcoma cell lines MG-63, HOS, MOS-J and POS-1 were treated with Alpelisib (0-50 µM) for 72 h and cell viability was measured using XTT assay. RESULTS: Alpelisib significantly inhibited cell growth of all osteosarcoma cell lines in a dose-dependent manner with IC50 ranging from 6-15 µM and IC90 ranging from 24-42 µM. [1] METHODS: PIK3CA wild-type cells (SNU638 and SNU668) and three PIK3CA mutant cells (SNU601, AGS, and MKN1) were treated with Alpelisib (5 µM) for 24 h, and cell cycle profiles were examined using Flow cytometry. RESULTS: Alpelisib treatment induced G0/G1 cell cycle arrest regardless of PIK3CA mutation status. In PIK3CA mutant cells (AGS and MKN1), there was a significant increase in the sub-G1 fraction, suggesting that Alpelisib increased apoptosis in these cell lines. [2] |
In vivo | METHODS: To assay anti-tumor activity in vivo, Alpelisib (12.5-50 mg/kg, methylcellulose 0.5%) was administered orally to Rj:NMRI-nude mice bearing human osteosarcoma HOS-MNNG once daily for twenty-two days. RESULTS: Alpelisib significantly reduced tumor volume in a dose-dependent manner. [1] METHODS: To investigate the modulatory effects on collagen, Alpelisib (12.5-50 mg/kg) was administered orally to nude mice bearing subcutaneous xenografts of Rat1-myr-p110α tumors once daily for eight days. RESULTS: Treatment with 12.5, 25, and 50 mg/kg of Alpelisib was well tolerated and produced dose-dependent and statistically significant antitumor effects with a T/C of 14.1% and regressions of 9.6% and 65.2%, respectively. [3] |
Cell Research | To evaluate the isoform-specific potency of NVP-BYL719 in a cell-based system, an N-terminally myristoylated form of each PI3K class IA isoform was expressed in Rat1 fibroblasts. The retroviral expression plasmid pBabePuro containing human p110α, p110β, and p110δ with an N-terminal myristoylation (myr) signal followed by an HA-tag were generated. Successfully infected Rat1 cells were selected in medium containing 4 μg/mL of puromycin, expanded and characterized for expression of the p110 isoforms. Transgenic expression of the myristoylated protein was confirmed by increased levels of phosphorylated Akt [1]. |
Animal Research | All in life experimentation and efficacy studies were conducted as described previously. Tumor xenografts were grown subcutaneously or orthotopically in nude mice or nude Rowett rats (Hsd: RH-Fox1rnu) by injection of 3 × 10^6 to 1 × 10^7 cells or implantation of tumor fragments of approximately 50 mg. Tumor-bearing animals mice were treated with either vehicle control, NVP-BYL719, or NVP-BKM120 (p.o., every day) at the doses indicated [1]. |
Alias | BYL-719 |
Molecular Weight | 441.47 |
Formula | C19H22F3N5O2S |
Cas No. | 1217486-61-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 60 mg/mL (135.91 mM) Ethanol: 2 mg/mL (4.53 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSO
main solution, add 300 μLPEG300
mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O
mix well and clarify
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
InhibitorPhosphoinositide 3-kinasePI3Kinhibitphosphorylationp110αcancerantineoplasticAKTBYL719metastasismutantAlpelisibBYL 719PIK3CAbreast